Ogilvy CommonHealth Worldwide evaluated how 14 major pharma companies were performing across six key categories:
- Social presence: How many social networks was the company on?
- Activity: Was the content kept fresh with regular updates?
- Engagement: Were the companies engaging their users and generating interest?
- Social network: How simple and intuitive was the connection between social networks?
- Virality: Was the content spread around the social sphere?
- Sommunity Size: How big was the community?
"I value my time off. Years ago when first going onto EHR, I could not connect from my house so I learned to get everything done before leaving the office. My time off was truly unconnected. This EHR change to mobile is going to necessitate another change in work flow for me.
There are two ways to approach this subject:
1. It will allow me to follow my patients more closely since I can get their lab results and follow-up data without being in the office. This will improve my relationship with my patients and result in more detailed care for them.
2. I will never really be out of the office. This could have legal ramifications.
The answer will likely be having a better buddy system and sign-out criteria in our practice. Right now, I have a buddy that will keep an eye on my charts and labs when I am away. We try to notify our buddies when they need to take over. Sometimes, it doesn't always work that way. So far, nothing serious has gotten missed … but we must remain vigilant in making sure follow up happens."
I prepared the chart on the left for the Pharma Marketing News article "DTC Ad Spending Rises from the Grave," which was published this Monday. You should compare this version of the chart to the one I published here on Pharma Marketing Blog last week (here).
This chart says 5% of pharma's 2014 DTC ad budget went to the Internet (excluding search), whereas the previous version says only 3%.
This chart says 63% of the budget went to TV, whereas the previous version says 70%.
I'll ignore print for now.
Determining the exact amount that the pharmaceutical industry spends on advertising via different media (TV, print, Internet, etc.) is a daunting task. Numbers regarding pharma DTC spending come from two sources: Nielsen and Kantar Media. Both report "measured media" spending, which includes TV, magazines, news-papers, radio, outdoor, and Internet (display ads only, not including search). Kantar tracks over 3,000 media sources throughout the US and Canada, which is a different methodology than that used by Nielsen. As a result, the numbers from these sources often do not match (for more on that, read "Making Sense of Pharma DTC Spending Trends").
Why the Differences?
Read more here.
Arundhati Parmar IBM announced Tuesday that it has formally created a business unit called IBM Watson Health, based in Boston, that will execute on its overarching goal to transform personal healthcare. To that end, the company is also launching the Watson Health Cloud to "provide a secure and open platform for physicians, researchers, insurers and companies focused on health and wellness solutions," a news release stated.
Les laboratoires pharmaceutiques peuvent désormais rembourser l'Assurance maladie en cas d'échec de certains traitements.
Le numérique, qui représente 5,5% du PIB et 3,3% des emplois en France, est une formidable opportunité à saisir... mais aussi une source de boulversement pour toutes les industries "traditionnelles", et en particulier les PME et ETI. Bpifrance Le Lab résume les grands mouvements à l'oeuvre dans une infographie.
It’s hard to find a pharma or medical device company these days that doesn’t have at least one mobile app in development. And now that, as of February 2015, the U.S. Food and Drug Administration (FDA) has issued guidance on which apps need to be regulated and which ones don’t, it will be interesting to see if this almost exponential development trend continues.
Federal guidance alone doesn’t guarantee an app’s success, and there is still plenty of playing field for developers in the health and wellness space for apps that do not require 510(k) submission. Therefore, developers and marketers alike must keep in mind these three key drivers of mobile health app adoption.
In a 2014 poll by QuantiaMD, only 37% of physicians surveyed said that they had recommended a mobile app to their patients. In another QuantiaMD poll, 42% of physicians said they would notrecommend a mobile health app to patients because there was no regulatory oversight (though the new FDA guidance should help with this). In addition, another 37% percent had no idea what mobile health apps are out there.
In spite of physicians being split on the utility of apps, consumers are downloading them at a rapid pace. In fact, it is estimated that within the next three years half of all smartphone and tablet users will have at least one mobile health or wellness app, like Lose It!, RunKeeper, or Glucose Buddy. But, downloading doesn’t necessarily mean they are using them! There is enormous opportunity for healthcare marketers to more effectively demonstrate the myriad of app benefits to patients and physicians alike.